A History of Innovation

For over 30 years, Mr. Olson has been a serial founder and entrepreneur in a broad range of medical device, diagnostic, biologic and biomaterial companies. Most recently Mr. Olson was the Founder, Chief Executive Officer and Board Member of Foresite Innovations, LLC, a private healthcare innovation and development holding company. He is accomplished in leading and motivating all levels of management in a variety of company sizes and industries both domestically and internationally. Mr. Olson previously served as CEO, President, and as a member of the Board of Directors for the Company while it was known as “Amedica Corporation.” Mr. Olson played a key role in the Company’s 2014 initial public offering and becoming listed on the NASDAQ Capital Market. Mr. Olson has served in senior executive roles of President, Chief Executive Officer and as a member of the Board Directors.

Dr. Bock has more than 20 years of experience in advanced ceramic research and development. Since joining SINTX 2008, he has participated in and led process and material development efforts for SINTX’s silicon nitride and subsequent discoveries of silicon nitride’s antipathogenic and biologic properties. Prior to joining SINTX, Dr. Bock was a researcher at the University of California at Santa Barbara, where he developed novel slurry systems for use in colloidal processing of advanced ceramic materials.

Dr. Bock is a co-author of more than 20 peer-reviewed technical papers in subject areas of ceramic science and biomaterials science. He served as a symposium organizer for the Surface Properties of Biomaterials Symposium at the annual Materials Science & Technology technical meeting from 2016 through 2019.

Dr. Bock holds a B.S. in Materials Science and Engineering from the University of Florida and a Ph.D. in Biomaterials from the Kyoto Institute of Technology.

Mr. Honigblum has over 35 years’ experience as a financier for emerging growth companies. His professional journey started as a stockbroker on Wall Street, where he transitioned into investment banking. Over time, he honed his craft at various investment banking boutiques in New York City before co-founding Creation Capital LLC and Creation Capital Advisors with offices in New York and Austin, Texas. The firm specialized in founding and funding breakthrough healthcare technologies. From 2003 to 2014 Mr. Honigblum was responsible for raising the Company’s private equity funding prior to its IPO in 2014. From 2006 to 2013, Mr. Honigblum was a member of the Board of Directors of Sintx (formerly Amedica Corporation). Mr. Honigblum was also instrumental in providing early-stage capital for Myriad Genetics (symbol MYGN), the first precision medicine diagnostic company credited with the discovery of BRCA1 and BRCA2 breast cancer genes. Additionally, he was an early-stage investor and financier for Acacia Biosciences, an early informational genomics company that merged with Rosetta Inpharmatics and subsequently acquired by Merck for $620 million. Mr. Honigblum has raised over $500 million for various ventures and has worked in different parts of the world, including London, Italy, Shanghai, China, and Los Angeles. He holds Series 7, 24, and 63 securities licenses and earned a Bachelor of Arts degree in Economics from the University of Texas at Austin.

Dr. Sonny Bal has served on the Board of Directors of SINTX Technologies since February 2012, and as Chairman of the Board since August 2014.

Dr. Bal previously served as Professor of Orthopaedic Surgery and Adjunct Professor of Material Sciences at the University of Missouri. He has >20 years of clinical experience as an orthopaedic surgeon and attorney, and is affiliated with several professional organizations. In addition to serving on the editorial boards of peer-refereed journals, Dr. Bal has researched and published extensively in ceramic science, and continues that work.

Dr. Bal holds an M.D. from Cornell University, an M.B.A. from Northwestern University, a J.D. from the University of Missouri and a Ph.D in Materials Engineering from the Kyoto Institute of Technology.

Dr. Froimson is currently a Principal at Riverside Health Advisors, a consulting company that provides strategic advice and services to health care executive leaders. Dr. Froimson served as past President of the American Association of Hip and Knee Surgeons, and as the Executive Vice President and Chief Clinical Officer of Trinity Health, a national non-profit Catholic healthcare system comprising 93 hospitals in 22 states.

Prior to the position at Trinity Health, Dr. Froimson was President and CEO of Euclid Hospital, a part of the Cleveland Clinic system. Dr. Froimson served as a staff surgeon in the Department of Orthopedic Surgery at the Cleveland Clinic for over 16 years, during which time he held many leadership positions including Medical Staff President, Vice Chair of the Orthopedic and Rheumatologic Institute, and member of the Board of Governors and Board of Trustees. Dr. Froimson serves on the Board of Directors of Pacira Biosciences, Inc., a publicly traded company on the NASDAQ Stock Market, and on the national Board of Directors of the Arthritis Foundation.

Dr. Froimson received a B.A. in philosophy from Princeton University, an M.D. from Tulane University School of Medicine, and an MBA from the Weatherhead School of Business at Case Western Reserve University. He completed his general surgical and orthopedic training at the University of California, Los Angeles and Columbia-Presbyterian Medical Center. He completed his fellowship in adult reconstructive surgery at the University Hospitals of Cleveland.

Dr. Froimson’s publications include several book chapters, and numerous abstracts and articles in scientific journals, including the Journal of Arthroplasty and the Journal of Bone and Joint Surgery. In addition, he serves in an editorial capacity for numerous scientific publications and is an internationally sought-after speaker and consultant on healthcare economics and business practices.

Eric A. Stookey currently serves as the Chief Operating Officer of OsteoRemedies®, Memphis, TN, where he has helped guide the medical device organization focused on infection remedies, since joining in 2015. Prior to joining OsteoRemedies®, Mr. Stookey served as the President of the Extremities-Biologics division at Wright Medical Group, Inc. (Nasdaq:WMGI) through 2014. He served in various other marketing and sales positions at Wright Medical Group, Inc. since 1995, including the Senior Vice President and Chief Commercial Officer, Vice President North American Sales, Senior Director of Sales – Central Region, and Director of Marketing for Large Joint Reconstruction Products. He also worked for DePuy Orthopedics, Inc. from 1993 to 1995.

Mr. Stookey earned his Masters of Business-Administration degree from Christian Brothers University and his Bachelor of Science degree in Business from the Indiana University School of Business. He previously served as an independent board member for Cartiva, Inc., Alpharetta, GA, until the successful acquisition of the business by Wright Medical Group, Inc in 2018.

David W. Truetzel has approximately 20 years of experience in the financial services and technology industries in both a consultative and operating capacity. Mr. Truetzel is a General Partner of Augury Capital Partners, which he co-founded in 2006. He was a General Partner of Hela Capital Partners, a partnership focused on leveraged buyouts in the financial services industry, from 2001 through 2005. In addition, Mr. Truetzel was a Managing Director of Gryphon Investments II, a technology focused venture capital firm, from 2000 through 2003.. Mr. Truetzel sits on the Board of Directors of Enterprise Bank, Inc, Elm Tree Funds II and Paranet, LLC.

Mr. Truetzel holds a B.S. in Accounting from Saint Louis University, an M.B.A. from The Wharton School and is a certified public accountant.

Jeffrey White has operated in the surgical device and biomaterials industry for 35 years as a senior sales, marketing, business development and chief executive in Fortune 500, mid-size and start-up firms. Mr. White is currently Principal, Medtech Advisory Group LLC, a firm that advises early and mid-stage medtech firms. Most recently he was Vice President of Product Management at MiMedx, the leading placental allograft firm. Prior to that he was Global Director of Business Development for Synthes, a $4 billion global orthopedic firm that was acquired by Johnson and Johnson in 2012. Mr. White is a member of the AOSpine and ISASS spine societies.

Previously, Mr. White was founder or CEO and board member of three start-up device firms, most recently Applied Spine, now doing business as Rachiotek. Prior to his start-up experiences, he was Senior Director of Business Development and Marketing at US Surgical Corporation where he was instrumental in rapidly growing the firm from $300 million to $1 billion as the highly acquisitive leader in the minimally invasive surgery segment. Mr. White also served as Vice President and General Manager, Surgery at Richard Allan Medical. As a business development and chief executive, Mr. White has executed more than 60 deals valued in excess of $ 1 billion.

Mr. White holds a B.S. cum laude in Biology from Union College in Schenectady, N.Y. and resides outside of Philadelphia, PA.